Sympatholytics: Alpha-2 agonists

Last updated: June 19, 2025

Sympatholytics: Alpha-2 agonists

ER Nursing Week 2

ER Nursing Week 2

Heart failure: Clinical
Cardiac work
Frank-Starling relationship
Atrial fibrillation
Regulation of pulmonary blood flow
Respiratory alkalosis
Respiratory system anatomy and physiology
Respiratory acidosis
Metabolic and respiratory alkalosis: Clinical
Acute respiratory distress syndrome: Clinical
Respiratory distress syndrome: Pathology review
Upper respiratory tract infection
Acute respiratory distress syndrome
Metabolic and respiratory acidosis: Clinical
Ventilation
Lung cancer
Standards of care for COVID-19 patients
Cardiovascular system anatomy and physiology
Introduction to the cardiovascular system
Control of blood flow circulation
Coronary circulation
Aortic valve disease
Resistance to blood flow
Heart failure
Heart failure: Pathology review
Normal heart sounds
Heart blocks: Pathology review
Abnormal heart sounds
Valvular heart disease: Clinical
Cardiac conduction system
Anatomy of the heart
Valvular heart disease: Pathology review
Rheumatic heart disease
Anatomy clinical correlates: Heart
Left-sided heart failure: Nursing process (ADPIE)
Post-COVID syndrome: Heart, lungs and clotting
Pericardial disease: Pathology review
Tuberculosis: Pathology review
Myocarditis
Dilated cardiomyopathy
Coronary artery disease: Pathology review
Myocardial infarction
ECG cardiac infarction and ischemia
Knowledge Shot: Is Santa Claus at risk of a heart attack
Coronary artery disease: Clinical
Pericarditis and pericardial effusion
Ischemia
Excitability and refractory periods
Antiplatelet medications
Non-corticosteroid immunosuppressants and immunotherapies
Aortic dissection
Aortic aneurysms and dissections: Clinical
Coronary steal syndrome
Venous thromboembolism: Clinical
Pericardial disease: Clinical
Carbon dioxide transport in blood
Zones of pulmonary blood flow
Hypertension: Clinical
Tricuspid valve disease
Sympatholytics: Alpha-2 agonists
Calcium channel blockers
Hypoplastic left heart syndrome
Positive inotropic medications
Familial hypercholesterolemia
Hyperlipidemia
Hypoxia
Laryngitis
Bacterial epiglottitis
Wolff-Parkinson-White syndrome
Atrioventricular nodal reentrant tachycardia (AVNRT)
Marfan syndrome
Brugada syndrome
Action potentials in pacemaker cells
Cardiomyopathies: Clinical
Long QT syndrome and Torsade de pointes
Atrioventricular block
Infective endocarditis: Clinical
Bundle branch block
Peripheral artery disease
Arterial disease
Peripheral vascular disease: Clinical
Cardiac tamponade
Cardiac contractility
ECG cardiac hypertrophy and enlargement
Aortic dissections and aneurysms: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pulmonary embolism
Stable angina
Angina pectoris
Prinzmetal angina
Ludwig angina
Unstable angina
Aneurysms
Pleural effusion
Obstructive lung diseases: Pathology review
Pneumonia: Clinical
Emphysema
Imaging features of COVID-19 (LifeBridge Health)

Transcript

Watch video only

Central anti-adrenergics are a class of medications that’s not very commonly used these days. Their mechanism of action is to target the adrenergic neurons in the central nervous system, and prevent them from effectively releasing the catecholamines: norepinephrine and epinephrine.

So, the nervous system is divided into the central nervous system, so the brain and spinal cord; and the peripheral nervous system, which includes all the nerves that connect the central nervous system to the muscles and organs. The peripheral nervous system can be divided into the somatic nervous system, which controls voluntary movement of our skeletal muscles; and the autonomic nervous system, which controls the involuntary movement of smooth muscles and glands of our organs.

Now, the autonomic nervous system - which includes both the sympathetic and parasympathetic nervous systems - is made up of a relay that includes two neurons. We’ll focus on just the sympathetic nervous system. Signals for the autonomic nervous system start in the hypothalamus, at the base of the brain. Hypothalamic neurons have really long axons that carry signals all the way down to the thoracic and lumbar spinal cord nuclei, where they synapse with preganglionic neuron cell bodies. Here, they release the neurotransmitter norepinephrine, which causes the preganglionic neurons to transmit the signals down their relatively short axon, which exits the central nervous system via the spinal cord. These short nerve fibers reach the nearby sympathetic ganglion, which consists of many postganglionic neuron cell bodies. The postganglionic neurons are also called adrenergic neurons, because they release the neurotransmitter norepinephrine, which is also called noradrenaline; and to a much lesser degree, epinephrine, or adrenaline. These two catecholamines activate the adrenergic receptors on many different organs, which allow the sympathetic nervous system to trigger the fight or flight response that increases the heart rate and blood pressure, as well as slowing digestion. All of this maximizes blood flow to the muscles and brain, and can help you either run away from a threat, or fight it, which is why it’s also called the “fight or flight response.”

Alright, so let’s zoom into the synapse between the hypothalamic neurons and the preganglionic neurons, which can be found throughout the brainstem and spinal cord. The presynaptic terminal contains loads of tiny synaptic vesicles, each of which stores thousands of norepinephrine molecules. But for norepinephrine to be there in the first place, a precursor amino acid, called tyrosine, is taken up by the adrenergic neuron and gets converted to L-dihydroxyphenylalanine, or L-DOPA for short, by an enzyme called tyrosine hydroxylase. Next, L-DOPA is converted by an enzyme called DOPA decarboxylase to dopamine, which is then packaged into the synaptic vesicles. The remaining dopamine will be broken down by a class of enzymes called monoamine oxidases, or MAOs for short. Okay, now once inside the vesicles, dopamine get converted into norepinephrine. And then, whenever the appropriate signal travels down the axon to the axon terminal, these vesicles fuse with the presynaptic membrane in order for norepinephrine to get released (or exocytosed) into the synaptic cleft and take action on the adrenergic receptors of the postsynaptic neuronal membrane. Okay, but this release of norepinephrine is controlled through negative feedback inhibition. So when a pre-synaptic nerve terminal is stimulated to release a bunch of norepinephrine in the synapse, some of it will bind to a special type of receptor called an alpha-2 adrenergic receptor, located on the presynaptic membrane. These alpha-2 receptors then inhibit further release of norepinephrine into the synapse, so the postsynaptic neuron doesn’t get over stimulated.

Alright, so medications that act on adrenergic neurons of the brainstem to inhibit adrenergic signal transmission are called central anti-adrenergics. What these do, is collectively oppose the effects of the sympathetic nervous system. So overall, the heart rate and blood pressure decrease, digestive processes speed up, and the fight-or-flight response gets blocked.

Key Takeaways

Alpha-2 agonists are a class of drugs that bind to alpha-2 adrenergic receptors and activate them, resulting in a range of physiological effects. Alpha-2 adrenergic receptor agonists include clonidine, guanabenz, and guanfacine. These medications stimulate alpha-2 adrenergic receptors on the presynaptic neurons in the CNS, especially those in the medulla. This decreases the release of norepinephrine in the sympathetic neurons, which leads to lower blood pressure. Alpha-2 agonists are used to treat various conditions such as anxiety, depression, attention deficit hyperactivity disorder (ADHD), and pain. Common side effects associated with the use of alpha-2 agonists include dry mouth, constipation, headache, dizziness, drowsiness, and fatigue.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "G-Protein–Coupled Receptors in Heart Disease" Circulation Research (2018)
  5. "α2A- and α2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands" Molecular Neurobiology (2018)
  6. "Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications" Anesthesia Progress (2015)
  7. "Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial" The Lancet (2019)